Elanco Animal Health Incorporated (NYSE:ELAN) Shares Acquired by KBC Group NV

KBC Group NV boosted its position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 264.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 323,502 shares of the company's stock after purchasing an additional 234,840 shares during the quarter. KBC Group NV owned about 0.07% of Elanco Animal Health worth $3,918,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ELAN. ORG Wealth Partners LLC purchased a new stake in shares of Elanco Animal Health in the 3rd quarter valued at approximately $29,000. AM Squared Ltd purchased a new stake in shares of Elanco Animal Health during the third quarter worth $34,000. Wilmington Savings Fund Society FSB purchased a new stake in Elanco Animal Health during the 3rd quarter worth about $35,000. Quarry LP acquired a new stake in Elanco Animal Health in the second quarter valued at approximately $40,000. Finally, Farther Finance Advisors LLC raised its holdings in shares of Elanco Animal Health by 158.7% in the 3rd quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company's stock valued at $49,000 after purchasing an additional 2,044 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company's stock.

Elanco Animal Health Price Performance

ELAN stock traded down $0.21 on Tuesday, reaching $11.52. The company had a trading volume of 5,664,497 shares, compared to its average volume of 4,670,991. Elanco Animal Health Incorporated has a 1 year low of $11.11 and a 1 year high of $18.80. The company has a market cap of $5.69 billion, a P/E ratio of 28.79, a PEG ratio of 2.71 and a beta of 1.42. The company's fifty day moving average is $12.13 and its 200 day moving average is $13.22. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, beating analysts' consensus estimates of $0.12 by $0.01. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same quarter in the previous year, the business posted $0.18 earnings per share. The company's revenue was down 3.6% on a year-over-year basis. On average, research analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Leerink Partners initiated coverage on Elanco Animal Health in a research report on Monday, December 2nd. They set a "market perform" rating and a $14.00 target price on the stock. Morgan Stanley decreased their target price on shares of Elanco Animal Health from $15.00 to $14.00 and set an "equal weight" rating for the company in a research note on Wednesday, January 29th. Stifel Nicolaus lowered their price objective on shares of Elanco Animal Health from $20.00 to $18.00 and set a "buy" rating on the stock in a research report on Tuesday, January 7th. Leerink Partnrs raised Elanco Animal Health to a "hold" rating in a report on Monday, December 2nd. Finally, Barclays upped their price target on shares of Elanco Animal Health from $19.00 to $20.00 and gave the stock an "overweight" rating in a research note on Friday, November 8th. One analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $16.29.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.